Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early conversion to osimertinib versus continuation of first-generation EGFR-TKIs in blood T790M-positive EGFR-mutant NSCLC
ChiCTR1800016544Phase 2Not yet recruiting
- Sponsor
- Hangzhou Cancer Hospital
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hangzhou Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2018; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800016544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016544.